Wolverhampton to develop anti-cancer therapy
The University of Wolverhampton is to play a central role in a £600k project to develop an anti-cancer therapy
The Jiangsu-UK Industrial Challenge Programme, co-funded by Innovate UK and Jiangsu Science and Technology Department in China, includes £90k of laboratory-based research to be carried out by the Cancer Research Group in the University’s Faculty of Science and Engineering.
Led by the Professor of Experimental Cancer Therapeutics, Weiguang Wang, the Cancer Research Group is developing a treatment based on Disulfiram, an existing drug used to treat alcoholism which is showing promising results in pre-clinical testing as a new anti-cancer therapy.
The international research collaboration will bring together academia and industry to focus on the development of the drug formulation to regulatory standards and testing its anti-cancer safety and efficacy.
Our focus is always on the patients, and we hope that we are able to offer an effective treatment to those people diagnosed with our target cancer
Professor Wang, UK Principal Investigator, said: “We have already demonstrated that our laboratory formulated PLGA encapsulated Disulfiram is effective against a range of cancer types.
“The funding we have secured from Innovate UK and the Jiangsu Science and Technology Department will allow us to move on to the next stage, which is to demonstrate that when our PLGA Disulfiram formulation is produced in a certified quality manufacturing environment in larger quantities, it still works as expected. Our focus is always on the patients, and we hope that we are able to offer an effective treatment to those people diagnosed with our target cancers.”
If pre-clinical testing of PLGA-Encapsulated Disulfiram continues to prove successful, then it is hoped that phase I clinical trials may commence in 2020.